Accrual Experience of National Cancer Institute Cooperative Group Phase III Trials Activated From 2000 to 2007

A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201

(2017) P. J. Loehrer et al.   JOURNAL OF CLINICAL ONCOLOGY

A sense of urgency: Evaluating the link between clinical trial development time and the accrual performance of CTEP-sponsored studies

(2017) S. Cheng et al.   JOURNAL OF CLINICAL ONCOLOGY

Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials

(2010) Anneke T Schroen et al.   Clinical Trials

Reply to Y.-T. Lan et al

(2010) Leonard L. Gunderson et al.   JOURNAL OF CLINICAL ONCOLOGY

Equipoise Lost: Ethics, Costs, and the Regulation of Cancer Clinical Research

(2010) David J. Stewart et al.   JOURNAL OF CLINICAL ONCOLOGY

Cancer Clinical Trials — A Chronic but Curable Crisis

(2010) Robert C. Young   NEW ENGLAND JOURNAL OF MEDICINE

Costs and Benefits of the National Cancer Institute Central Institutional Review Board

(2009) Todd H. Wagner et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical Cancer Advances 2008: Major Research Advances in Cancer Treatment, Prevention, and Screening—A Report From the American Society of Clinical Oncology

(2008) Eric Winer et al.   JOURNAL OF CLINICAL ONCOLOGY